Revenue stood at ₹794 crore marking a decline of 43% in the quarter under review as against ₹1,390 crore for the corresponding quarter last year.

Natco Pharma has reported a stark profit decline in the first quarter, largely driven by reduced sales of its leading cancer drug, lenalidomide. This led to a pronounced drop in…

Revenue stood at ₹794 crore marking a decline of 43% in the quarter under review as against ₹1,390 crore for the corresponding quarter last year.